Your browser doesn't support javascript.
loading
Synchrotron-based photon activation therapy effect on cisplatin pre-treated human glioma stem cells.
Ceresa, Cecilia; Nicolini, Gabriella; Semperboni, Sara; Requardt, Herwig; Le Duc, Geraldine; Santini, Carlo; Pellei, Maura; Bentivegna, Angela; Dalprà, Leda; Cavaletti, Guido; Bravin, Alberto.
Afiliación
  • Ceresa C; Experimental Neurology Unit and Milan Center for Neuroscience, Department of Surgery and Translational Medicine, University of Milano-Bicocca, Monza, Italy.
  • Nicolini G; Experimental Neurology Unit and Milan Center for Neuroscience, Department of Surgery and Translational Medicine, University of Milano-Bicocca, Monza, Italy.
  • Semperboni S; Experimental Neurology Unit and Milan Center for Neuroscience, Department of Surgery and Translational Medicine, University of Milano-Bicocca, Monza, Italy.
  • Requardt H; Biomedical Beamline (ID17), European Synchrotron Radiation Facility (ESRF), Grenoble, France.
  • Le Duc G; Biomedical Beamline (ID17), European Synchrotron Radiation Facility (ESRF), Grenoble, France.
  • Santini C; School of Science and Technology - Chemistry Division, University of Camerino, Camerino, Italy.
  • Pellei M; School of Science and Technology - Chemistry Division, University of Camerino, Camerino, Italy.
  • Bentivegna A; Experimental Neurology Unit and Milan Center for Neuroscience, Department of Surgery and Translational Medicine, University of Milano-Bicocca, Monza, Italy.
  • Dalprà L; Experimental Neurology Unit and Milan Center for Neuroscience, Department of Surgery and Translational Medicine, University of Milano-Bicocca, Monza, Italy.
  • Cavaletti G; Experimental Neurology Unit and Milan Center for Neuroscience, Department of Surgery and Translational Medicine, University of Milano-Bicocca, Monza, Italy cecilia.ceresa1@unimib.it.
  • Bravin A; Biomedical Beamline (ID17), European Synchrotron Radiation Facility (ESRF), Grenoble, France.
Anticancer Res ; 34(10): 5351-5, 2014 Oct.
Article en En | MEDLINE | ID: mdl-25275028
ABSTRACT

BACKGROUND:

Glioblastoma multiforme (GBM) is one of the deadliest cancers characterized by very limited sensitivity to chemo- and/or radiotherapy. The presence of GBM stem-like cells in the tumor might be relevant for GBM treatment resistance.

AIM:

To provide a proof-of-concept of the efficacy of photon activation therapy (PAT) using monochromatic synchrotron radiation (SR), in killing GBM stem cells pre-treated with cisplatin. MATERIALS AND

METHODS:

Irradiation was performed using a 1-8 Gy dose range and energies just above or below the platinum K-shell edge (78.39 keV) or with a conventional X-ray source. Cells were exposed to drug concentrations allowing 90% cell survival, mimicking the unfavourable tissue distribution generally achieved in GMB patients.

RESULTS:

a significant enhancement in cell lethality was observed using SR compared to conventional X-ray irradiation.

CONCLUSION:

PAT deserved to be further explored in in vivo models based on GBM stem-like cells.
Asunto(s)
Palabras clave
Buscar en Google
Base de datos: MEDLINE Asunto principal: Células Madre Neoplásicas / Neoplasias Encefálicas / Cisplatino / Sincrotrones / Fotones / Glioblastoma Idioma: En Revista: Anticancer Res Año: 2014 Tipo del documento: Article
Buscar en Google
Base de datos: MEDLINE Asunto principal: Células Madre Neoplásicas / Neoplasias Encefálicas / Cisplatino / Sincrotrones / Fotones / Glioblastoma Idioma: En Revista: Anticancer Res Año: 2014 Tipo del documento: Article